ON-01溶瘤单纯疱疹病毒治疗复发性胶质瘤的1/2期单臂研究
本研究为单臂1/2期临床试验,评估工程化重组溶瘤单纯疱疹病毒1型ON-01在30例复发性WHO 4级胶质瘤患者中的短期安全性和疗效。患者接受立体定向引导下瘤内注射ON-01,中位总生存期为12.0个月(95%CI 10.1-13.9),中位无进展生存期为3.0个月(95%CI 1.7-4.3),2年总生存率为27.7%(95%CI 12.6%-45.0%)。治疗总体安全,未观察到神经毒性,疗效可能与HVEM表达水平相关。
要点
- ON-01瘤内注射在复发性WHO 4级胶质瘤中显示短期安全性,无神经毒性证据。
- 中位OS为12.0个月,中位PFS为3.0个月,2年OS率为27.7%。
核心结论
- 瘤内注射ON-01在复发性恶性胶质瘤患者中表现出安全性及疗效,且无神经毒性证据。
- 对ON-01的治疗反应可能与HVEM表达水平相关。
研究设计与样本
- 单臂1/2期临床试验,纳入30例复发性WHO 4级胶质瘤患者。
- 患者接受立体定向引导下瘤内注射ON-01。
- 主要终点为评估ON-01治疗的短期(28天)安全性;次要终点包括PFS、OS和2年OS率;探索性目标为识别预测疗效的肿瘤相关生物标志物。
主要发现
- 30例患者中13例(43.3%)为男性,中位年龄50.0岁(范围22-75)。
- 共报告36例1级、12例2级和2例3级不良事件。
- 中位OS为12.0个月(95%CI 10.1-13.9),中位PFS为3.0个月(95%CI 1.7-4.3),2年OS率为27.7%(95%CI 12.6%-45.0%)。
- 7例复发性多灶性胶质瘤患者在ON-01治疗后非注射部位病灶出现消退。
临床怎么用
- 对于复发性WHO 4级胶质瘤,瘤内注射ON-01可作为潜在治疗选择,需关注短期安全性。
- HVEM表达水平可能有助于筛选可能从ON-01治疗中获益的患者。
局限性
- 单臂设计,无对照组,样本量较小(30例),结论需进一步随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis of patients with recurrent WHO grade 4 glioma is poor, particularly in glioblastoma, which has a median survival of approximately 6 months and no effective treatment options. We evaluated the short-term (28-day) safety and efficacy of ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in patients with recurrent WHO grade 4 glioma. METHODS: In this single-arm, phase 1/2 clinical trial, eligible patients received intratumoral injections of ON-01 under stereotactic guidance. The primary endpoint was to assess the short-term safety profile of ON-01 treatment. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the 2-year OS rate. An exploratory objective was to identify tumor-related biomarkers predictive of treatment efficacy. RESULTS: Of the 30 patients treated with ON-01, 13 (43.3%) were male, and the median age was 50.0 years (range, 22-75). A total of 36 grade 1, 12 grade 2, and 2 grade 3 adverse events were reported. Among all treated patients, the median OS was 12.0 months (95% CI, 10.1-13.9), median PFS was 3.0 months (95% CI, 1.7-4.3), and 2-year OS rate was 27.7% (95% CI, 12.6%-45.0%). Seven patients with recurrent multifocal gliomas demonstrated regression of non-injection site lesions following ON-01 therapy. Furthermore, patients with elevated expression of herpesvirus entry mediator exhibited significantly prolonged survival (P = .015). CONCLUSIONS: Intratumoral infusion of ON-01 appeared safe and demonstrated efficacy in patients with recurrent malignant glioma, with no evidence of neurotoxicity. The therapeutic response to ON-01 may be associated with HVEM expression levels.
引用
- Zeng W, Wang P, Fang S, et al. ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: A single-arm, phase 1/2 study. Neuro Oncol. 2026. PMID: 41527280. doi:10.1093/neuonc/noag005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。